GRM5 and fragile X syndrome: Taken together with the results from the present study, the field of FXS appears poised for major breakthroughs in treatment using inhibitors targeting increased mGluR5 signaling or cyclic AMP (cAMP) production; offering promising new directions for future pharmacological research, as well as approaches to the challenges associated with scanning this population.